‘Extraordinary’ t-cell cancer therapy results generate excitement
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
List view / Grid view
16 February 2016 | By Victoria White
In one study, the engineered T-cells induced complete remission in 94% of patients with acute lymphoblastic leukaemia...
16 February 2016 | By Victoria White
MGB Biopharma and the University of Strathclyde are to extend their existing collaboration to develop novel MGB anti-infectives...
15 February 2016 | By Victoria White
Researchers say drug discovery processes are becoming unsustainably expensive despite huge technological advances because the wrong methods are being used…
12 February 2016 | By Victoria White
The latest report from the Review on Antimicrobial Resistance says that vaccines and other alternatives can play a vital role in tackling the rise of drug-resistant infections...
12 February 2016 | By Victoria White
Scientists tested nimbolide, natural extract derived from India's neem tree, against pancreatic cancer in cell lines and mice...
9 February 2016 | By Dr Bissan Al-Lazikani and Elizabeth Coker, The Institute of Cancer Research, London
Dr Bissan Al-Lazikani and Elizabeth Coker discuss canSAR: the first public domain example of Big Data for drug discovery...
8 February 2016 | By Victoria White
Peptidyl arginine deiminase 4 (PAD4) is a protein that plays a role in the development of inflammatory diseases like arthritis...
5 February 2016 | By Victoria White
New research suggests that drugs to prevent, rather than encourage, cell death might be effective at fighting cancer - contrary to how many of the current chemotherapy drugs work...
3 February 2016 | By Victoria White
XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumours, including breast, gastric and non-small cell lung cancers...
3 February 2016 | By Victoria White
A new ‘roadmap’ document published today outlines how The London Cancer Hub will become a world-leading life-science campus...
3 February 2016 | By Victoria White
The enhanced agreement will accelerate Adaptimmune’s lead clinical cancer programme, an affinity enhanced T-cell immunotherapy targeting NY-ESO-1...
2 February 2016 | By Victoria White
The £60 million enables the company to maximise the potential of its DUB platform and advance a series of DUB inhibitors...
29 January 2016 | By Victoria White
Researchers have identified the cells that likely give rise to the brain tumour subtype Group 4 medulloblastoma, removing a barrier to developing more effective targeted therapies....
29 January 2016 | By SMi Group
Registration now live for the 5th annual ADC Summit taking place at the Holiday Inn Kensington Forum, London, UK on the 23rd – 24th May 2016...
29 January 2016 | By Victoria White
The lab headed by Thomas Helleday at Karolinska Institutet and Biovica are to collaborate to improve evaluation of new, promising cancer therapies...